AU2013352437B2 - Lyophilized formulation of TAT-NR2B9c - Google Patents

Lyophilized formulation of TAT-NR2B9c Download PDF

Info

Publication number
AU2013352437B2
AU2013352437B2 AU2013352437A AU2013352437A AU2013352437B2 AU 2013352437 B2 AU2013352437 B2 AU 2013352437B2 AU 2013352437 A AU2013352437 A AU 2013352437A AU 2013352437 A AU2013352437 A AU 2013352437A AU 2013352437 B2 AU2013352437 B2 AU 2013352437B2
Authority
AU
Australia
Prior art keywords
arg
prt
synthesized
artificial sequence
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013352437A
Other languages
English (en)
Other versions
AU2013352437A1 (en
Inventor
Jonathan David Garman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of AU2013352437A1 publication Critical patent/AU2013352437A1/en
Application granted granted Critical
Publication of AU2013352437B2 publication Critical patent/AU2013352437B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013352437A 2012-11-28 2013-11-25 Lyophilized formulation of TAT-NR2B9c Ceased AU2013352437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
US61/730,952 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (2)

Publication Number Publication Date
AU2013352437A1 AU2013352437A1 (en) 2015-07-09
AU2013352437B2 true AU2013352437B2 (en) 2018-04-12

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013352437A Ceased AU2013352437B2 (en) 2012-11-28 2013-11-25 Lyophilized formulation of TAT-NR2B9c

Country Status (18)

Country Link
US (1) US20140162957A1 (enExample)
EP (1) EP2925338B8 (enExample)
JP (1) JP6427104B2 (enExample)
KR (1) KR102166374B1 (enExample)
CN (2) CN109106941A (enExample)
AU (1) AU2013352437B2 (enExample)
CA (1) CA2892965C (enExample)
DK (1) DK2925338T3 (enExample)
ES (1) ES2725598T3 (enExample)
HR (1) HRP20190707T1 (enExample)
HU (1) HUE043820T2 (enExample)
LT (1) LT2925338T (enExample)
MX (1) MX365325B (enExample)
PL (1) PL2925338T3 (enExample)
PT (1) PT2925338T (enExample)
SI (1) SI2925338T1 (enExample)
TR (1) TR201905787T4 (enExample)
WO (1) WO2014085349A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US7060268B2 (en) * 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
US20070140981A1 (en) * 2003-12-24 2007-06-21 Archimedes Development Limited Intranasal compositions
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain
US20120252731A1 (en) * 2007-12-05 2012-10-04 Nono, Inc. Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2551190A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EA017291B1 (ru) * 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP5801197B2 (ja) * 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
CA2765169C (en) * 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US7060268B2 (en) * 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
US20070140981A1 (en) * 2003-12-24 2007-06-21 Archimedes Development Limited Intranasal compositions
US20120252731A1 (en) * 2007-12-05 2012-10-04 Nono, Inc. Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
John F.Carpenter et al., "RATIONAL DESIGN OF STABLE LYOPHILIZED PROTEIN FORMULATIONS: THEORY AND PRACTICE", Pharmaceutical Biotechnology *

Also Published As

Publication number Publication date
KR102166374B1 (ko) 2020-10-15
WO2014085349A1 (en) 2014-06-05
HUE043820T2 (hu) 2019-09-30
US20140162957A1 (en) 2014-06-12
CA2892965A1 (en) 2014-06-05
LT2925338T (lt) 2019-05-10
JP2016502537A (ja) 2016-01-28
BR112015012422A2 (pt) 2017-09-12
EP2925338A4 (en) 2016-05-25
SI2925338T1 (sl) 2019-09-30
JP6427104B2 (ja) 2018-11-21
CA2892965C (en) 2021-06-01
EP2925338B1 (en) 2019-03-27
ES2725598T3 (es) 2019-09-25
CN105101986A (zh) 2015-11-25
DK2925338T3 (da) 2019-05-06
CN109106941A (zh) 2019-01-01
MX2015006784A (es) 2015-10-29
HRP20190707T1 (hr) 2019-10-04
TR201905787T4 (tr) 2019-05-21
KR20150094656A (ko) 2015-08-19
PL2925338T3 (pl) 2019-11-29
AU2013352437A1 (en) 2015-07-09
CN105101986B (zh) 2018-09-25
EP2925338B8 (en) 2019-05-22
HK1215793A1 (en) 2016-09-15
EP2925338A1 (en) 2015-10-07
MX365325B (es) 2019-05-29
PT2925338T (pt) 2019-05-31

Similar Documents

Publication Publication Date Title
US11911438B2 (en) Chloride salt of TAT-NR2B9C
EP2925338B1 (en) Lyophilized formulation of tat-nr2b9c
US10912817B2 (en) Prelyophilized, lyophilized and reconstituted formulations comprising TAT-NR2B9C with d-amino acids, histidine and trehalose
US20220096383A1 (en) Lyophilized formulation of tat-nr2b9c with acetylation scavenger
HK40044216A (en) Chloride salt of tat-nr2b9c
HK1215793B (en) Lyophilized formulation of tat-nr2b9c
HK1236205A1 (en) Chloride salt of tat-nr2b9c
HK1236205B (en) Chloride salt of tat-nr2b9c

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired